General
Preferred name
cytarabine
Synonyms
cytarabine hydrochloride ()
Ara-Cytidine,Arabinosyl Cytosine,U-19920 ()
Cytosine-1-beta-D-arabinofuranoside hydrochloride ()
Cytosine ¦Â-D-arabinofuranoside hydrochloride ()
Cytosine ¦Â-D-arabinofuranoside ()
Ara-C ()
Cytosine arabinoside ()
Cytosine ??-D-arabinofuranoside ()
Arabinocytidine ()
Cytosine ??D-arabinofuranoside hydrochloride ()
Cytosine ??D-arabinofuranoside ()
2(1H)-Pyrimidinone, 4-amino-1-y-D-arabinofuranosyl ()
Cytarabine (U-19920A) ()
Cytarabin,Ara-C,Arabinofuranosyl Cytidine,Cytosine ¦Â-D-arabinofuranoside,Cytosine arabinoside,NSC 63878,NSC 287459,U-19920A ()
Arabinocytosine ()
Arabinosyl Cytosine ()
Cytarabinum ()
Aracytidine ()
Cytosar-U ()
Cytosar ()
NSC-287459 ()
Cytarabine liposome ()
Alexan 100 ()
Depocyt ()
U-19,920 ()
Aracytine ()
Cytarabinoside ()
Tarabine Pfs ()
Aracytin ()
Spongocytidine ()
U 19920a ()
U-19920 ()
Ara-Cytidine ()
Depocyte ()
Alexan ()
Cytarabine hcl ()
NSC-63878 ()
Cytosine Arabinoside hydrochloride ()
U-19920A ()
Cytarabine-13C3 ()
P&D ID
PD003178
CAS
147-94-4
71838-92-1
69-74-9
Tags
drug candidate
natural product
probe
drug
available
Approved by
PMDA
EMA
FDA
First approval
1969
Drug Status
investigational
approved
Drug indication
Antineoplastic
Antiviral,Antiviral
Acute lymphoblastic leukaemia
Antiviral
Max Phase
Phase 4
Phase 3
Probe info
Probe selectivity
family-selective
Probe type
calculated probe
Probe sources
Probe Miner (suitable probes)
Probe targets
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. (GtoPdb)
DESCRIPTION inducer of DNA damage (Informer Set)
DESCRIPTION Selective inhibitor of DNA synthesis (LOPAC library)
Cell lines
586
Organisms
3
Compound Sets
30
AdooQ Bioactive Compound Library
A10265
Axon Medchem Screening Library
3238
Cayman Chemical Bioactives
16069
28805
CeMM library of unique drugs (CLOUD)
ChEMBL Approved Drugs
CHEMBL803
ChEMBL Drugs
CHEMBL803
CHEMBL1256472
Concise Guide to Pharmacology 2017/18
4827
Concise Guide to Pharmacology 2019/20
4827
Concise Guide to Pharmacology 2021/22
4827
Concise Guide to Pharmacology 2023/24
4827
Drug Repurposing Hub
DrugBank
DB00987
DrugBank Approved Drugs
DB00987
DrugCentral
770
DrugCentral Approved Drugs
770
DrugMAP
DMZD5QR
DrugMAP Approved Drugs
DMZD5QR
Enamine BioReference Compounds
Guide to Pharmacology
4827
Informer Set
62690
LOPAC library
NCATS Inxight Approved Drugs
04079A1RDZ
NIH Clinical Collections (NCC)
Novartis Chemogenetic Library (NIBR MoA Box)
Prestwick Chemical Library
Probe Miner (suitable probes)
Q00987/95279
ReFrame library
Selleckchem Bioactive Compound Library
Cytarabine(Cytosar-U)
cytarabine-hydrochloride
TargetMol Bioactive Compound Library
T1272
Welcome Trust Cancer Drugs
1006
External IDs
89
Properties
(calculated by RDKit )
Molecular Weight
243.09
Hydrogen Bond Acceptors
8
Hydrogen Bond Donors
4
Rotatable Bonds
2
Ring Count
2
Aromatic Ring Count
1
cLogP
-2.56
TPSA
130.83
Fraction CSP3
0.56
Chiral centers
4.0
Largest ring
6.0
QED
0.45
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Compound status
FDA
Target
DNA polymerase (alpha/delta/epsilon)
DNA synthesis
RNA
DNA
POLA1, POLB, POLD1, POLE
DNA synthesis inhibitor
Apoptosis related,Autophagy,DNA/RNA Synthesis,Nucleoside Analog/Antimetabolite
DNA/RNA Synthesis
Pathway
DNA replication
DNA Damage/DNA Repair
MOA
DNA polymerase inhibitor
Antimetabolites
DNA Polymerase Inhibitors
Ribonucleotide Reductase inhibitor
Member status
member
Indication
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
Therapeutic Class
Anticancer Agents
Source data